Efficacy, Compliance And Toxicity Factors Are Affecting The Rate Of Normalization Of Body Iron Stores In Thalassemia Patients Using The Deferiprone And Deferoxamine Combination Therapy

The international committee on chelation (ICOC) of deferiprone (L1) and deferoxamine (DFO) combination therapy was the first protocol reported to have achieved normal range body iron store levels (NRBISL) in β-thalassemia major (β-TM) patients. A follow-up study in eight β-TM patients has been designed to investigate the factors affecting the rate of iron removal leading to NRBISL. The patients had variable serum ferritin [mean ± SE (standard error) =1692 ± 366, range 539–3845 μg/L)] and magnetic resonance imaging (MRI) T2* relaxation times cardiac (mean ± SE =11.1 ± 2.5, range 4.5–24.2 ms) and liver (mean ± SE = 4.3 ± 1.8, range 1.4–14 ms). Organ function, blood and other biochemical parameters were regularly monitored for toxicity. The ICOC L1 (80–100 mg/kg/day) and DFO (40–60 mg/kg, at least 3 days per week) combination therapy caused an increase in cardiac (mean ± SE =30.2 ± 2.3, range 22–41 ms) and liver (mean ± SE =27.6 ± 2.8, range 9.1–35 ms) T2* and reduction in serum ferritin (mean ± SE = 158 ± 49, range 40–421 μg/L) to within the NRBISL. The rate of normalization was variable and in one case was achieved within 9 months, whereas the longest was about 3 years. The initial iron load, the rate of transfusions, the combination dose protocol and the level of compliance were the major factors affecting the rate of normalization of the iron stores. No serious toxicity was observed during the study period, which lasted a total of 24.7 patient years.

[1]  Massimo Midiri,et al.  Deferasirox, Deferiprone and Desferrioxamine Treatment in Thalassemia Major Patients: Cardiac Iron and Function Comparison Determined by Quantitative Magnetic Resonance Imaging Early Release Paper Deferasirox, Deferiprone and Desferrioxamine Treatment in Thalassemia Major Patients: Cardiac Iron and , 2022 .

[2]  G. Kontoghiorghes,et al.  Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy , 2010, European journal of haematology.

[3]  G. Kontoghiorghes,et al.  New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores , 2010, British journal of haematology.

[4]  T. Coates,et al.  The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. , 2010, Blood.

[5]  G. Kontoghiorghes.  Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities , 2010, Expert opinion on drug safety.

[6]  G. Kontoghiorghes,et al.  Maintenance of Normal Range Body Iron Store Levels for up to 4.5 Years in Thalassemia Major Patients Using Deferiprone Monotherapy , 2010, Hemoglobin.

[7]  S. Shah,et al.  Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases , 2010, Expert opinion on drug safety.

[8]  G. Chouliaras,et al.  Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major , 2010, British journal of haematology.

[9]  G. Kontoghiorghes.  A New Era in Iron Chelation Therapy: The Design of Optimal, Individually Adjusted Iron Chelation Therapies for the Complete Removal of Iron Overload in Thalassemia and other Chronically Transfused Patients , 2009, Hemoglobin.

[10]  E. Eracleous,et al.  Uses and Limitations of Serum Ferritin, Magnetic Resonance Imaging T2 and T2* in the Diagnosis of Iron Overload and in the Ferrikinetics of Normalization of the Iron Stores in Thalassemia Using the International Committee on Chelation Deferiprone/Deferoxamine Combination Protocol , 2009, Hemoglobin.

[11]  G. Kontoghiorghes.  Prospects for introducing deferiprone as potent pharmaceutical antioxidant. , 2009, Frontiers in bioscience.

[12]  G. Abbruzzese,et al.  Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation , 2008, Movement disorders : official journal of the Movement Disorder Society.

[13]  E. Eracleous,et al.  Long Term Comparative Studies in Thalassemia Patients Treated with Deferoxamine or a Deferoxamine/Deferiprone Combination. Identification of Effective Chelation Therapy Protocols , 2008, Hemoglobin.

[14]  K. Kyriacou,et al.  Myocyte Damage and Loss of Myofibers is the Potential Mechanism of Iron Overload Toxicity in Congestive Cardiac Failure in Thalassemia. Complete Reversal of the Cardiomyopathy and Normalization of Iron Load by Deferiprone , 2008, Hemoglobin.

[15]  M. Tsironi,et al.  Intensive Chelation Therapy in β-Thalassemia and Possible Adverse Cardiac Effects of Desferrioxamine , 2007, International Journal of Hematology.

[16]  Nathalie Boddaert,et al.  Selective iron chelation in Friedreich ataxia: biologic and clinical implications. , 2007, Blood.

[17]  D. Pennell,et al.  A Randomized, Placebo-Controlled, Double-Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance , 2007, Circulation.

[18]  G. Kontoghiorghes,et al.  Effective Combination Therapy of Deferiprone and deferoxamine for the Rapid Clearance of Excess Cardiac IRON and the Prevention of Heart Disease in Thalassemia. The Protocol of the International Committee on Oral Chelators , 2006, Hemoglobin.

[19]  G. Kontoghiorghes.  Iron Mobilization From Transferrin And Non-Transferrin-Bound-Iron by Deferiprone. Implications in the Treatment of Thalassemia, Anemia of Chronic Disease, Cancer and Other Conditions , 2006, Hemoglobin.

[20]  E. Eracleous,et al.  Low Serum Ferritin Levels are Misleading for Detecting Cardiac Iron Overload and Increase the Risk of Cardiomyopathy in Thalassemia Patients. The Importance of Cardiac Iron Overload Monitoring Using Magnetic Resonance Imaging T2 and T2* , 2006, Hemoglobin.

[21]  E. Eracleous,et al.  Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations. , 2005, Current medicinal chemistry.

[22]  G. Kontoghiorghes,et al.  Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators. , 2005, Current medicinal chemistry.

[23]  Marvin D Nelson,et al.  Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. , 2004, Blood.

[24]  I. Papassotiriou,et al.  Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. , 2003, Haematologica.

[25]  D N Firmin,et al.  Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. , 2001, European heart journal.

[26]  M. Cappellini,et al.  Survival and Disease Complications in Thalassemia Major , 1998, Annals of the New York Academy of Sciences.

[27]  G. Kontoghiorghes,et al.  Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals. , 1993, Arzneimittel-Forschung.

[28]  A. Piga,et al.  SURVIVAL AND CAUSES OF DEATH IN THALASSAEMIA MAJOR , 1989, The Lancet.